Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

BACKGROUND: Standard treatment with sunitinib for patients with metastatic renal cancer provides an ‘on-off’ schedule (daily administration of a 50-mg capsule for 4 weeks, followed by a 2-week break; consecutive 6-week cycles). We developed an alternative intermittent schedule to reduce the toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694422/
https://www.ncbi.nlm.nih.gov/pubmed/28895069
http://dx.doi.org/10.1007/s40268-017-0209-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694422/
https://www.ncbi.nlm.nih.gov/pubmed/28895069
http://dx.doi.org/10.1007/s40268-017-0209-5

Ejemplares similares